---
title: "Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized Trials"
id: "medrxiv-8-heterogeneous-treatment-effects-in-hfpef-distinguishing-drug-specific-response"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-8-heterogeneous-treatment-effects-in-hfpef-distinguishing-drug-specific-response"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.06.26357251v1?rss=1"
published_at: "2026-07-09T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized Trials
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-8-heterogeneous-treatment-effects-in-hfpef-distinguishing-drug-specific-response
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.06.26357251v1?rss=1)
- **Published At:** 2026-07-09T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome comprising multiple pathophysiological phenotypes. HFpEF trials have largely enrolled diverse populations and reported average treatment effects, consistently yielding neutral results that may obscure drug-specific benefits within distinct subgroups. To address this issue, we employ an interaction-based that incorporates treatment-by-variable interactions to uncover drug-specific responses. Methods: We leveraged four HFpEF clinical trials (TOPCAT, RELAX, NEAT-HFpEF, INDIE-HFpEF) and developed a framework comprising two complementary approaches. The first employed a prognostic responder model to evaluate whether conventional responder definitions reflect treatment-specific benefit or instead capture favorable clinical trajectories common to both treatment and placebo groups. The second used an interaction-based individual treatment effect (ITE) modeling to identify baseline variables that modify therapy effect, distinguishing drug-specific response from prognostic phenotypes. Results: Although the prognostic responder model demonstrated good discrimination, further analisys suggested it primarily captured a prognostic signal associated with favorable clinical trajectories common to both treatment and placebo arms.
## Clinical Analysis & Structured Key Points
medRxiv (Clinical Preprints) published a clinical update in Research Highlights on 09 Jul 2026. The item focuses on Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized Trials. Review the original article for the full source wording and details.
## Related Clinical Research

- [Polypill Improved Ejection Fraction in HFrEF Trial](https://medichelpline.com/clinical-feed/nature-4-polypill-for-heart-failure-with-reduced-ejection-fraction-the-poly-hf.md)
- [Biochemical profile of spironolactone use in hospitalized patients with hypotonic hyponatraemia](https://medichelpline.com/clinical-feed/pubmed-42752325.md) (DOI: 10.1080/07853890.2026.2718576)
- [Spironolactone and early eGFR declines in HFpEF: TOPCAT Americas post-hoc analysis](https://medichelpline.com/clinical-feed/pubmed-41961632.md) (DOI: 10.1093/ejhf/xuag099)
- [Coexisting AL (λ) amyloidosis and POEMS syndrome presenting as refractory heart failure: a case re](https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-a-rare-coexistence-of-immunoglobulin-light-chain-amyloidosis-and-poems-syndrome.md)
- [Finerenone Prescriptions in the United States (2021–2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular‐Kidney‐Metabolic Space](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-12-finerenone-prescriptions-in-the-united-states-2021-2024-by-physician-specialty.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.